Clinical Impact of MRD Assessment in Chronic Lymphocytic Leukemia

Enjoy an interactive discussion with an expert clinician about the real-world utility of minimal residual disease assessment in Chronic Lymphocytic Leukemia (CLL). A review of the data supporting the clinical use of the clonoSEQ® Assay will also be provided. Through the partnership of Adaptive Biotechnologies, you are invited to attend this meeting free of charge.